3rd Quarter Financial Results for FYE 3/2008 (Consolidated)
Name of listed company: TERUMO CORPORATION( URL http://www.terumo.com/ )Company code number: 4543
Representative:
Akira Takahashi, President
Please address all communications to:
Kunio Kimishima, General Manager, Corporate Communication Dept.

January 30, 2008

Exchange where listed: TSE
Location of headquarters (prefecture):
Tokyo

Phone: +81 / 3-3217 - 6550

1. Consolidated Financial Highlights for the nine months ended December 2007 - Unaudited(From April 1, 2007 to December 31, 2007)(1) Consolidated financial results(Note: The amounts shown below ignore values of less than a million yen)
Net sales

Operating income(Millions of yen)

Nine months ended December, 2007
Nine months ended December, 2006
Year ended March, 2007

% (Millions of yen)

231,438
205,148
276,43912.8
11.7

Net income per share

52,44945,22858,455

Ordinary income% (Millions of yen)

16.0
16.9

Net income% (Millions of yen)

52,933
46,25458,025

14.4
17.7

%

34,75229,54337,23217.6
18.0

Net income per share,
fully diluted(Yen)(Yen)

Nine months ended December, 2007176.06
Nine months ended December, 2006
146.20Year ended March, 2007
185.00* The percentages shown next to net sales, operating income, ordinary income and net income represent year-on-year changes.
(2) Consolidated financial position
Total assets
December 31, 2007
December 31, 2006
March 31, 2007

(Millions of yen)

(Millions of yen)

428,525
356,615367,147

306,580
279,830
289,248(3) Consolidated statements of cash flows
Cash flows fromoperating activities
Nine months ended December, 2007
Nine months ended December, 2006
Year ended March, 2007

Shareholders’ equity

Cash flows frominvesting activities

Equity ratio

Book value per share%

71.5
78.5
78.8
Cash flows fromfinancing activities(Yen)

1,561.45
1,407.38
1,454.71
Cash and cash equivalents,end of the period(Millions of yen)

(Millions of yen)

(Millions of yen)

(Millions of yen)

45,66828,83943,123(23,239)(12,427)(19,917)

16,434(28,365)(28,637)

81,921
36,69543,049(4) Changes in scope of consolidation and in application of the equity method in significant subsidiaries.
(elimination): None
Consolidation (new) :None
Equity method (new) :None(elimination): None
(5) All financial results for the consolidated financial period from April 1, 2007 to December 31, 2007 are not audited
by independent auditors.

2. Consolidated Financial Statements(1) Consolidated Balance Sheet

I.Current Assets
Cash and cash equivalents
Trade receivable notes/accounts
Inventories
Other current assets
II.Fixed Assets
1. Tangible fixed assets
Building and structures
Machinery and transportation equipment
LandConstruction in progress
Other tangible assets
2. Intangible fixed assets
3. Investments and other assets
Investment in securities
Other investments and other assets
Total Assets

December 31, 2006
Amount%163,283
45.8
36,93570,244
44,211
11,891
193,332
54.2
114,864
32.2
44,94430,572
20,30011,718
7,328
41,116
11.5
37,35010.5
33,173
4,177
356,615
100.0

I.Current Liabilities
Trade payable notes/accounts
Short-term bank loans
Other current liabilities
II.Long-term Liabilities
Long-term bank loans
Reserve for retirement allowance
Other long-term liabilities
Total Liabilities
I.Shareholders' Equity
Capital stock
Capital surplus
Retained earnings
Treasury stock
II.Evaluation difference and foreign currency exchange adjustments
Evaluation difference of investment securities
Gain / loss on deferred hedge
Foreign currency translation adjustments
Ⅲ.Minority Interests
Total Net Assets

61,891
24,081476
37,333
14,893440
11,361
3,091
76,785
271,828
38,71659,030207,524(33,443)
7,945
7,983
(2)
(36)
56
279,830

Total Liabilities and Net Assets

356,615

17.3

December 31, 2007
Amount%219,936
51.3
83,702
74,402
49,846
11,985208,58848.7
114,775
26.8
45,51335,67920,4406,599
6,542
38,666
9.0
55,14612.9
51,186
3,960
428,525
100.0

0.0
78.5

108,375
26,52935,22846,617
13,569
422
5,440
7,706
121,945
295,691
38,71659,030244,037(46,093)
10,790
11,395(604)
97306,580100.0

428,525

4.2

21.5
76.3

2.2

25.3

(Millions of yen)March 31, 2007
Amount%171,576
46.7
44,536
69,15545,631
12,253
195,570
53.3
115,643
31.5
45,09232,004
20,296
11,493
6,756
40,524
11.1
39,402
10.7
34,802
4,599
367,147
100.0

0.0
71.5

65,891
25,725236
39,92912,007
436
6,506
5,064
77,899279,50738,71659,030215,213(33,453)
9,672
8,947
725
68
289,248

0.0
78.8

100.0

367,147

100.0

3.2

28.5
69.0

2.5

17.9

3.3

21.2
76.1

2.7

(2) Consolidated Statement of Income

Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating income
Non-operating income / expenses
Ordinary income
Extraordinary income / expenses
Income before taxes
Corporate, inhabitant and enterprise taxes
Minority interests
Net income for the period

Nine months ended
December 31, 2006
Amount%205,148
100.0
91,94344.8
113,205
55.2
67,97633.2
45,22822.0
1,025
46,25422.5(773)
45,48022.2
15,928
829,543
14.4

Nine months ended
December 31, 2007
Amount%231,438
100.0
103,93144.9
127,507
55.1
75,05732.4
52,44922.7
483
52,93322.9
914
53,84823.3
19,071
24
34,752
15.0(Millions of yen)
Year ended
March 31, 2007
Amount%276,439100.0
123,11244.5
153,32655.5
94,871
34.3
58,45521.2(429)
58,02521.0(952)
57,072
20.619,824
1637,232
13.5

(3) Statement of changes in net assets

Nine-month period ended December 31, 2007 (from April 1, 2007 to December 31, 2007)

Beginning of period
Changes during this fiscal accounting period
Cash dividends from retained earnings
Net income for the period
Acquisition of treasury stock(Decrease) increase of items during the period except those included inshareholders' equity
Total changes during this fiscal accounting periodEnding of period

Beginning of period
Changes during this fiscal accounting period
Cash dividends from retained earnings
Net income for the period
Acquisition of treasury stock(Decrease) increase of items during the period except those included inshareholders' equity
Total changes during this fiscal accounting periodEnding of period(Millions of yen)

Shareholders' equity
Retained
Capital stock
Capital surplus
Treasury stockearnings
38,71659,030215,213(33,453)(5,928)34,752

38,71659,03028,824
244,037

Shareholders'equity total
279,507(12,640)(5,928)34,752(12,640)(12,640)(46,093)

16,184
295,691

Evaluation difference and foreign currency exchange
adjustments
EvaluationEvaluation
Foreign currency difference and Minority interests Net assets total
difference of
foreign currencytranslation
investment
exchange
adjustments
securities
adjustments total
8,947
725
9,672
68
289,248(5,928)34,752(12,640)
2,447
2,447
11,395(1,329)(1,329)
(604)

1,117
1,117
10,790

29
29
97

1,147
17,331
306,580

Shareholders' equity
Retained
Capital stock
Capital surplus
Treasury stockearnings
38,71659,030183,391(13,449)

Shareholders'equity total
267,689

Fiscal year ended March 31, 2007 (from April 1, 2006 to March 31, 2007

Beginning of period
Changes during this fiscal accounting period
Cash dividends from retained earnings
Directors' bonuses
Net income for the period
Acquisition of treasury stock(Decrease) increase of items during the period except those included inshareholders' equity
Total changes during this fiscal accounting periodEnding of period

Beginning of period
Changes during this fiscal accounting period
Cash dividends from retained earnings
Directors' bonuses
Net income for the period
Acquisition of treasury stock(Decrease) increase of items during the period except those included inshareholders' equity
Total changes during this fiscal accounting periodEnding of period(5,278)(132)
37,232

38,71659,03031,821
215,213(20,004)(5,278)(132)
37,232(20,004)(20,004)(33,453)

11,817
279,507

Evaluation difference and foreign currency exchange
adjustments
Evaluation
Evaluation
Foreign currency difference and Minority interests Net assets total
difference of
foreign currencytranslation
investment
exchange
adjustments
securities
adjustments total
7,367(1,747)5,619
49273,359(5,278)(132)
37,232(20,004)
1,5801,580
8,947

2,472
2,472
725

4,052
4,052
9,672

1818
68

4,071
15,888289,248

(4) Consolidated Statement of Cash Flows

Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Effect of exchange rate changes on cash and cash equivalents
Change in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of period

Nine months ended
December 31, 2006
28,839(12,427)(28,365)684(11,268)
47,96336,695

Nine months ended
December 31, 2007
45,668(23,239)
16,4348
38,87143,04981,921(Millions of yen)
Year ended
March 31, 2007
43,123(19,917)(28,637)516(4,914)47,96343,049December 31, 2006
195,329

December 31, 2007
204,180(Millions of yen)March 31, 2007
196,452

Nine months ended
December 31, 2006
11,608Nine months ended
December 31, 2007
11,773(Millions of yen)
Year ended
March 31, 2007
16,792Nine months ended
December 31, 2006
43-

Nine months ended
December 31, 2007
11,059(Millions of yen)
Year ended
March 31, 2007
43-

75
12728

147-(5)Notes
Relating to balance sheet

Accumulated depreciation of tangible assets

Relating to statement of income
Main items among selling, general and administrative expenses

R&D expenditure
Main items among extraordinary income / expenses

Gain on sales of property, plant and equipment
Gain arising from change in equity accounted interest
Loss on disposal of property, plant and equipment
Loss on restructuring in overseas operation
Compensation for retired directors
Provision for retirement benefits for directors and corporate auditors

1956012728

3. Segment Information(1) Sales results by product segment(Millions of yen)
Nine months ended Nine months ended
December 31, 2006 December 31, 2007
Amount%Amount%Disposable medical equipment
Pharmaceuticals
Blood transfusion systems
General hospital products
Catheter systems
Cardiovascular systems
Vascular grafts
Cardiac & Vascular products
CAPD systems
Diabetes care products
Other productsHome health care products
TotalChanges
Amount%9.7%

59,09628.8%

64,850

28.0%

5,753

29,756

14.5%

31,970

13.8%

2,214

7.4%

14,217

6.9%

17,434

7.6%

3,216

22.6%

103,06950.2%

114,25449.4%

11,184

10.9%

46,531

22.7%

57,79725.0%

11,26624.2%

26,48512.9%

28,353

12.2%

1,868

7.1%

7,207

3.5%

7,687

3.3%

479

6.7%

80,223

39.1%

93,83840.5%

13,614

17.0%

5,510

2.7%

5,429

2.3%

(80)

(1.5%)

9,395

4.6%

10,800

4.7%

1,404

15.0%

6,949

3.4%

7,116

3.1%

166

2.4%

23,34510.1%
231,438 100.0%

1,490
26,2906.8%
12.8%

21,855
10.7%
205,148 100.0%

Note 1) Main Products belonging to each product segment
Product segment

Main Products

Disposable medical equipmentSyringes, Needles, Solution Administration sets, I.V.catheters,
Blood collection tubes, Electronic medical devices, etc.
I.V.solution, Prefilled syringes, Nutritional products, etc.
Blood bags, Blood transfusion administration sets, medical
electronic devices for blood collection, etc.
PTCA dilation catheters, Coronary stents, Guide wires,
Angiographic catheters, Cerebral aneurysm coils, etc.
Roller pumps, Hollow fiber oxygenators, Blood circuits, etc.
Artificial vascular grafts
Dialysis solution, etc.
Blood glucose monitors, etc.
Home oxygen systems, Home nutritional products, DigitalThermometers, Electronic sphygmomanometers, etc.

Pharmaceuticals
Blood transfusion systems
Catheter systems
Cardiovascular systems
Vascular grafts
CAPD systems
Diabetes care products
Other products(2) Sales results by region(Millions of yen)
Nine months ended Nine months ended
December 31, 2006 December 31, 2007
Amount%Amount%JapanEurope
America
Asia and Others
TotalChanges
Amount%115,275

56.2%

123,201

53.2%

7,925

6.9%

34,771

17.0%

42,254

18.3%

7,483

21.5%

38,02918.5%

43,511

18.8%

5,481

14.4%

22,471
9.7%
231,438 100.0%

5,399
26,29031.6%
12.8%

17,072
8.3%
205,148 100.0%